Linalool: From Sleep to Balance — Same Molecule, Different Role

If you followed the Sleep Series from a few weeks ago, you already know linalool.

It's the primary bioactive constituent of lavender. It's a positive allosteric modulator of

GABA-A receptors (not a negative allosteric modulator). Its mechanism has been confirmed by the fact that it's blocked when researchers administer flumazenil — a benzodiazepine antagonist — confirming it acts at the benzodiazepine binding site.

We discussed this in the context of nighttime wind-down. But here's what I didn't spend

enough time on then. In six randomized, double-blind, placebo-controlled clinical trials of Silexan — the oral standardized lavender preparation that is primarily linalool — researchers found:

✦ 80 mg/day for 10 weeks: comparable to lorazepam (Ativan 0.5 mg) for generalized

anxiety

✦ Head-to-head vs. paroxetine (Paxil 20 mg): linalool outperformed the SSRI on anxiety

symptoms with an effect size of 0.87

✦ Zero sedation reported across all clinical trials

✦ No abuse potential identified

✦ Co-occurring depressive symptoms also improved — confirmed in a meta-analysis of

all five trials

The critical word for a daytime formula: zero sedation.

This is what makes linalool genuinely interesting here. It engages the GABAergic system

— reducing the anxious charge and emotional reactivity that drives stress responses —

without the sedation that makes benzodiazepines unusable during the day.

The mechanism is real. The human trials are real. And linalool's role in the Calm &

Balance formula is designed to provide that GABAergic layer to the broader four-compound

system.

Tomorrow: how all four work together as one integrated pharmacological strategy.

— Dr. Murse | CannabisDNP

The Formulator Is on the Label.

─────────────────────

For adult use only (21+) · Educational content only

Resources:

Kasper S, Gastpar M, Müller WE, Volz HP, Möller HJ, Schläfke S, Dienel A. Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacol. 2014 Jun;17(6):859-69. doi: 10.1017/S1461145714000017. Epub 2014 Jan 23. PMID: 24456909.

Kasper S, Eckert A. Silexan in anxiety, depression, and related disorders: pharmacological background and clinical data. Eur Arch Psychiatry Clin Neurosci. 2025 Sep;275(6):1621-1635. doi: 10.1007/s00406-024-01923-8. Epub 2024 Oct 25. PMID: 39453446; PMCID: PMC12500767.